US FDA Lays Out High And Low Options At MDUFA Talks
This article was originally published in Clinica
Minutes from the most recent Medical Device User Fee Act negotiation meeting, posted by the US FDA, suggest regulators and industry are getting closer to agreeing on components of a MDUFA IV proposal. Returning to the negotiating table on May 16, the agency presented two proposals to industry that are approximately $30m apart.
You may also be interested in...
FDA and industry say they have reached tentative agreement, but finance subgroup says more discussion needed.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.